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Study of paradoxical response to chemotherapy in 
tuberculous pleural effusion 
S. A. AL-MAJED 
Department of Medicine, College of Medicine, King Saud University, Saudi Arabia 
Background: Paradoxical worsening of disease, in spite of effective chemotherapy for tuberculosis, has been 
reported to occur in cases of intracranial tuberculoma, lymph node, and pulmonary tuberculosis. However, 
only rare case reports describe such paradoxical response in tuberculosis pleurisy. 
Methods: Sixty-one patients with proven tuberculous pleural effusion were retrospectively screened in Riyadh, 
Saudi Arabia, in three major hospitals to look systematically at the incidence and features of paradoxical 
response. 
Results: Paradoxical increase in the size of the effusion was detected in 10 of 61 patients. In six patients, the 
effusion became massive with worsening of dyspnoea requiring the use of corticosteroids in five patients and 
therapeutic aspiration in all six. However, complete resolution occurred in all 10 patients within l-3 months. 
Three out of the 10 patients developed residual pleural thickening. 
Conclusion: An incidence of 16% (10/61) paradoxical worsening of tuberculous effusion following the start of 
anti-tuberculous treatment has been documented. This resulted in respiratory distress necessitating therapeutic 
re-aspiration in six of 10 patients. 
Introduction 
Unusual expansion or new formation of tubercu- 
lous lesion during treatment has been referred to as 
‘paradoxical response’ (1). Paradoxical worsening of 
the tuberculous lesions has been frequently described 
to occur weeks or months after the start of anti- 
tuberculous therapy in the case of lymphadenopathy 
or intracranial tuberculoma (l-3). Similarly, para- 
doxical response has been observed during treat- 
ment of pulmonary tuberculosis which can lead to an 
adult respiratory distress syndrome (4). On the con- 
trary, paradoxical worsening of tuberculous pleural 
effusion is mentioned only in rare case reports (5). 
Therefore, this systematic study was conducted to 
find the incidence and features of the phenomenon in 
tuberculous pleural effusion. 
Materials and Methods 
This is a retrospective study which screened all 
patients with tuberculous pleural effusion diagnosed 
between July 1991 and September 1994 in the follow- 
ing hospitals - King Khalid University Hospital, 
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Chest Hospital, National Guard Hospital, Riyadh, 
Saudi Arabia. The criteria for the diagnosis of 
tuberculous effusion were either caseating granuloma 
in the pleural biopsy, acid-fast bacilli (AFB) in 
the pleural fluid or biopsy, or positive culture of 
Mycobacterium tuberculosis in the fluid. 
Patients with other aetiology of pleural effusion 
such as congestive heart failure, pneumonia, malig- 
nancy or collagen disorder were excluded from this 
study. Patients with parenchymal involvement in 
addition to the tuberculous pleural effusion were also 
excluded. Parenchymal involvement was excluded for 
two reasons: the fluid extended up to the chest wall in 
a ‘typical’ mantle distribution on P.A. and lateral film 
which Frazer et al. considered as evidence that the 
underlying lung is free of disease (6). Cases which did 
not have that typical appearance were excluded, 
In addition, six of 10 patients had a computerized 
tomography at the time of worsening of effusion 
which again confirmed the lack of parenchymal lung 
involvement. A standard regimen of rifampicin, iso- 
niazide, pyrazinamide and ethambutol or streptomy- 
cin were given for the first 2 months. Thereafter, only 
rifampicin and isoniazide were continued for an 
additional 4 months. Compliance was ensured by 
supervised treatment for the first 2 months (all were 
inpatients). All chest radiography films performed 
before and after the start of chemotherapy were 
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Table 1 Patients’ data 
Case Age/ Initial 





following Degree of Time of Long-term 
worsening of worsening worsening outcome 
the effusion of effusion of effusion Intervention of effusion 
1 20/M Fever, cough, Left-sided Dyspnoea Massive 1 week Pleural fluid Total 
chest pain moderate effusion aspiration resolution 
2 30/M Cough, fever Bilateral - Right-sided 1 month - Total 
mild effusion moderate resolution 
3 35/M Fever, Right-sided Dyspnoea Massive 1 week Fluid aspiration Pleural 
chest pain moderate effusion +prednisolone orally thickening 
4 33/M Fever, cough Left-sided mild - Moderate 3 weeks - Pleural 
weight loss +pneumothorax thickening 
5 60/M Dypnoea, Left-sided mild - Moderate 1 month - Total 
cough, fever resolution 
6 40/F Cough fever, Right-sided mild Dyspnoea Massive 1 month Intra-pleural Total 
chest pain hydrocortisone 200 mg resolution 
+ pleura1 aspiration 
I 32/M Cough, chest Left-sided mild Dyspnoea Massive 1 month Fluid aspiration+ Total 
pain, fever prednisolone orally resolution 
8 69/M Cough, fever, Right-sided Dyspnoea Massive 14 days Fluid aspiration+ Pleural 
chest pain moderate prednisolone orally thickening 
9 60/F Cough, Right-sided mild Dyspnoea Massive 1 week Fluid aspiration + Total 
dyspnoea worsened prednisolone orally resolution 
10 SO/M Cough, chest Left-sided mild Moderate 2 weeks - Total 
pain, fever resolution 
reviewed. The pleural effusion was graded as small 
(less than one-third of the hemithorax), moderate 
(one-third to two-thirds of the hemithorax), or mas- 
sive (more than two-thirds of the hemithorax). The 
grading of effusion is identical to that used by other 
workers (7) and it was adopted in this study for the 
sake of uniformity. Frazer et al. (6) defined moderate 
effusion as ‘extending to about the mid portion of the 
hemithorax on a plain chest X-ray’. This is roughly 
similar to the one adopted by Lee et al. (7) and that 
used in this paper. 
Results 
Increase in the size of the pleural effusion was 
detected in 10 of 61 patients. Table 1 gives the details 
of the 10 cases with worsening tuberculous effusion. 
Patients 6 and 7 had positive AFB smear and culture 
in pleural fluid, while Patients 5 and 10 grew A4. 
tuberculosis in crushed pleural biopsy only; the four 
isolates were sensitive for INH, rifampicin and 
ethambutol. Eight of 10 patients had caseating 
granuloma in the pleural biopsy. The remaining two 
patients (Patients 5 and 7) had non-caseating granu- 
loma. In six patients, the effusion became massive, 
and moderate in four patients. The six patients whose 
effusion became massive experienced worsening of 
dyspnoea and cough, and were subjected to repeats 
of pleural aspiration and biopsy, bronchoscopy, and 
CT scan. The test revealed no other pathology apart 
from tuberculosis. One of the six cases received 
200 mg hydrocortisone intrapleurally once, while 
another four patients were given prednisolone 30 mg 
orally daily, tapered over several weeks. The sixth 
patient required only therapeutic aspiration to relieve 
dyspnoea. There was gradual improvement in symp- 
toms but total resolution of fluid occurred in l-3 
months. Three of 10 patients developed residual 
pleural thickening. 
Discussion 
Although short-course chemotherapy for tubercu- 
losis is associated with good outcome and minimal 
drug toxicity (8,9); paradoxical increase of the disease 
manifestations is documented to occur weeks or 
months following the administration of anti- 
tuberculous drugs (l-5). 
This paradoxical response has been frequently 
reported in tuberculous lymphadenitis (2) and 
intracranial tuberculoma (3,lO). Up to 30% of 
patients with tuberculous lymphadenopathy show 
such a reaction, and tuberculomas start enlarging up 
to 7 months following chemotherapy before full 
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Plate 1 Chest X-ray of Case 8, 5 days after start of 
chemotherapy. 
resolution is obtained (2). In contrast, such a reaction 
is rarely reported in tuberculous effusion. Vilaseca 
et al. reported contralateral pleural effusion during 
chemotherapy for tuberculous pleurisy in one patient 
occurring 3 weeks after initiation of chemotherapy 
(5). Other workers have described tuberculous ef- 
fusion appearing 34 weeks after the start of chemo- 
therapy for pulmonary tuberculosis in two patients 
(11). 
The present study is the first, to the author’s 
knowledge, to look systematically at the incidence of 
such paradoxical reaction in a series of tuberculous 
effusion, and establish an incidence of 16% (10/61) 
which is less than the 30% documented in the case of 
tuberculous lymphadenopathy (2). 
The fact that the patients in this study received 
potent drugs (INH, rifampicin, PZA) under super- 
vision and showed full resolution eventually supports 
the view that this is a genuine paradoxical response 
and not the effect of ineffective chemotherapy. 
Workers have speculated on the mechanisms of the 
paradoxical response in cases of lymphadenitis and 
tuberculomas, and attributed it to ‘immunological 
rebound’ by which the improved cell-mediated 
immunity after treatment coincided with excessive 
antigen load (bacterial cell-wall residues) resulting 
from rapid bacterial lysis (1,12,13). The same 
Plate 2 Chest X-ray of Case 8, 2 weeks after start of 
chemotherapy. 
workers also suspected that rapid bactericidal drugs 
like INH and rifampicin could be worse offenders 
than bacteriostatic drugs. The same mechanisms 
could be operational in the case ‘of pleural effusion. 
Corticosteroids are known to modify the severity 
of the clinical manifestations of tuberculosis (14,15). 
However, there is no data that corticosteroids could 
prevent the paradoxical worsening seen in various 
organs. We feel a prospective double-blind study is 
warranted in view of the diagnostic dilemma posed 
by paradoxical worsening of the disease and in view 
of the fact that six patients in the present study 
developed respiratory distress which could have been 
prevented by corticosteroids. 
In conclusion, an incidence of 16% paradoxical 
worsening of tuberculous pleural effusion was docu- 
mented. This could result, not infrequently, in respir- 
atory distress necessitating therapeutic re-aspiration. 
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